Otsuka, Lundbeck Sue Alvogen to Block Copies of Abilify Maintena

Alvogen Inc.’s proposed generic version of Abilify Maintena infringes six patents for the schizophrenia treatment that an Otsuka Holdings Co. unit exclusively licenses to H. Lundbeck A/S, a federal lawsuit said.

Otsuka Pharmaceutical Co. and Lundbeck alleged Alvogen’s copies of its injectable treatment’s 300- and 400-milligram vials of aripiprazole, Abilify Maintena’s active ingredient, infringe US Patent Nos. 10,525,057, 10,980,803, 11,154,553, 11,344,547, 11,400,087, and 11,648,347, according to a complaint filed Feb. 14 and docketed Tuesday in the US District Court for the District of Delaware. The patents cover methods of providing aripiprazole to patients ...